MAPT and Alzheimer disease: Whether VAMP-2 could be a useful addition to NFL to specifically monitor synapse engagement and therapeutic response, particularly in AD clinical trials would be an interesting avenue worth pursuing; as anti-tau and anti-Aβ are common therapies, there is a need for an alternative surrogate measure of cognitive performance not directly affected by the drug.